Navigation Links
MiMedx Announces Record First Quarter 2013 Results
Date:5/1/2013

l measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Revenue Breakdown The Company distinguishes its revenue between three primary regenerative medicine specialties, "Wound Care," "Surgical & Sports Medicine," and "Other," and reports its revenue in these categories. Revenue for the Company's EpiFix® grafts comprises the Wound Care category. Its Surgical & Sports Medicine specialty is comprised of the Company's injectable, orthopedic and surgical applications for its AmnioFix® grafts. The "Other" category of the MiMedx regenerative medicine specialties includes the Company's tissue revenue from its dental and ophthalmic applications and products from its HydroFix® technology. In the quarter, 54% of MiMedx sales volume was for Wound Care, 40% for Surgical and Sports Medicine and 6% for "Other."

Outlook for Second Quarter and Full Year 2013The Company reaffirmed its previously communicated goals for second quarter of 2013 revenue to be in the range of $11.5 million to $13.5 million and full year 2013 revenue to be in the range of $50 million to $60 million. The point within the range of revenue goals will be largely dependent on whether and how quickly the remaining Medicare intermediaries begin to reimburse for the Company's EpiFix® allografts recognizing that there are a number of factors that are beyond the Company's ability to influence.

Earnings CallMiMedx management will host a live broadcast of its first quarter results conference call on Wednesday, May 1, 2013, beginning at 10:30 a.m. eastern time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
2. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
3. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
4. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
5. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
6. MiMedx Group, Inc. Announces Release Date for 2012 Fourth Quarter Results
7. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
8. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
9. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
10. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Sept. 16 Genoptix, Inc.,(Nasdaq: GXDX ), a ... the UBS Global Life Sciences Conference,scheduled to take place ... September 22,- 25, 2008., Douglas Schuling, Senior Vice ... on Monday, September 22, beginning at,approximately 3:30 pm EDT. ...
... answer to ensuring a safe supply of drinking water ... or where water contamination is rife. Writing in the ... India explain how carbon nanotubes could replace conventional materials ... access to safe drinking water will continue to grow ...
... Symmetry Medical Inc.,(NYSE: SMA ), a leading ... and other medical markets, announced today that,Brian S. Moore, ... the UBS Global Life Sciences Conference at The Grand ... 25, 2008 at 11:30 a.m. ET., A live ...
Cached Biology Technology:Genoptix Announces Participation at the UBS Global Life Sciences Conference 2Water purification down the nanotubes 2Symmetry Medical to Present at UBS Global Life Sciences Conference 2
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... ON (Dec. 22, 2011) - Drugs used to overcome ... study led by Gerry Wright, scientific director of the ... McMaster University. "Our study found that certain proteins, ... to proteins important in cancer," says Wright about the ...
... 2011(BRONX, NY) Researchers at Albert Einstein College of Medicine ... mechanism by which cells control the survival of messenger RNA ... pertain to mRNAs that help regulate cell division and could ... research is described in today,s online edition of the journal ...
... tragic losses to life, property, and the environment. But ... from done. Without vegetation, bare, burnt soil lies vulnerable ... regeneration. Now Assaf Inbar, a graduate student ... together with his supervisors Prof. Marcelo Sternberg of the ...
Cached Biology News:Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 3Reclaiming the land after a forest fire 2
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... have been designed to save time and ... interested in eliminating the recycling and resterilizing ... individually packaged, RNase/DNase free, non-pyrogenic and antistatic. ... product number, created to easily match Cornings ...
... Phosphatase Detection Kit (Catalog number SCR004) is ... phenotypic assessment of ES cell differentiation by ... separately from CHEMICON are the monoclonal antibodies ... Number MAB4354), which permit the detection of ...
... The SYS203 is a complete, ... measurement in small samples, as is ... system is designed around Instechs miniature ... of an inch in diameter (3.2 ...
Biology Products: